Author:
Petti M. C.,Tafuri A.,Latagliata R.,Aloe Spiriti M. A.,Montefusco E.,Mancini M.,Meloni G.,Petrucci M. T.,Spadea A.,Redi R.,Alimena G.,Mandelli F.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference18 articles.
1. Nocentini G (1996) Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Hematol 22:89–126
2. Chabner BA, Allegra CJ, Curt GA, et al. (1996) Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 9th edn. Mc Graw-Hill, New York, pp 1233–1287
3. Vaughan WP, Bierman PJ, Reed EC, Glenn LD, Kessinger A, Armitage JO (1992) High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent. Semin Oncol 19:110–115
4. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91:1533–1541
5. Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A (1984) Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute non lymphoblastic leukemia. Cancer Genet Cytogenet 11:332–350